RO.CH

267

+1.91%↑

NOVN.CH

99.29

+0.88%↑

BANB.CH

68.95

+0.44%↑

RO.CH

267

+1.91%↑

NOVN.CH

99.29

+0.88%↑

BANB.CH

68.95

+0.44%↑

RO.CH

267

+1.91%↑

NOVN.CH

99.29

+0.88%↑

BANB.CH

68.95

+0.44%↑

RO.CH

267

+1.91%↑

NOVN.CH

99.29

+0.88%↑

BANB.CH

68.95

+0.44%↑

RO.CH

267

+1.91%↑

NOVN.CH

99.29

+0.88%↑

BANB.CH

68.95

+0.44%↑

Search

Lonza Group AG

Închisă

SectorSănătate

554.2 0.43

Rezumat

Modificarea prețului

24h

Curent

Minim

554

Maxim

555

Indicatori cheie

By Trading Economics

Venit

119M

426M

Vânzări

59M

3.6B

P/E

Medie Sector

52.039

34.427

EPS

4.31

Randament dividend

0.73

Marjă de profit

11.913

Angajați

19,299

EBITDA

764M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+20.6% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.73%

2.47%

Următoarele câștiguri

23 oct. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-4.9B

38B

Deschiderea anterioară

553.77

Închiderea anterioară

554.2

Sentimentul știrilor

By Acuity

50%

50%

157 / 374 Clasament în Healthcare

Lonza Group AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 iul. 2025, 08:30 UTC

Câștiguri
Principalele dinamici ale pieței

Lonza Shares Rise After Outlook Lift for Core Business

9 mai 2025, 05:18 UTC

Câștiguri

Lonza Doesn't Expect Tariff Hit, Backs Outlook for CDMO Business

18 feb. 2025, 12:22 UTC

Achiziții, Fuziuni, Preluări

Lonza Picks BofA, Centerview Partners for Capsules Unit Sale, Bloomberg Law Says, Citing Sources

23 iul. 2025, 08:00 UTC

Market Talk
Câștiguri

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

23 iul. 2025, 04:44 UTC

Câștiguri

Lonza 1H Sales Grew 19% at Constant Currency

23 iul. 2025, 04:43 UTC

Câștiguri

Lonza 1H Core Ebitda Margin 29.6%

23 iul. 2025, 04:43 UTC

Câștiguri

Lonza: Margins Will Be Only Minimally Affected

23 iul. 2025, 04:42 UTC

Câștiguri

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

23 iul. 2025, 04:42 UTC

Câștiguri

Lonza: This Is Mainly From Weakening of U.S. Dollar

23 iul. 2025, 04:38 UTC

Câștiguri

Lonza 1H Net Pft CHF426M

23 iul. 2025, 04:37 UTC

Câștiguri

Lonza Backs 2025 View for CHI Business

23 iul. 2025, 04:36 UTC

Câștiguri

Lonza Had Seen CDMO Business Core Ebitda Margin Approaching 30% in 2025

23 iul. 2025, 04:36 UTC

Câștiguri

Lonza Sees CDMO Business Core Ebitda Margin of 30%-31% in 2025

23 iul. 2025, 04:35 UTC

Câștiguri

Lonza Had Expected 2025 CDMO Business Sales Growth at Constant Currency of About 20%

23 iul. 2025, 04:35 UTC

Câștiguri

Lonza Expects 2025 CDMO Business Sales Growth at Constant Currency of 20%-21%

23 iul. 2025, 04:33 UTC

Câștiguri

Lonza Upgrades 2025 Full-Year CDMO Sales and Margin Outlook

23 iul. 2025, 04:32 UTC

Câștiguri

Lonza 1H EBITDA CHF1.01B

23 iul. 2025, 04:32 UTC

Câștiguri

Lonza 1H Core Ebitda CHF1.06B

23 iul. 2025, 04:32 UTC

Câștiguri

Analysts Saw Lonza 1H Sales at CHF3.51B

23 iul. 2025, 04:32 UTC

Câștiguri

Analysts Saw Lonza 1H Core Ebitda at CHF1.00B

23 iul. 2025, 04:31 UTC

Câștiguri

Lonza 1H Sales CHF3.58B

23 iul. 2025, 04:31 UTC

Câștiguri

Lonza Backs 2025 View

25 iun. 2025, 05:27 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Lonza Group Looks Well-placed to Benefit From U.S. Pharma Trade Policy -- Market Talk

28 mai 2025, 05:38 UTC

Market Talk

Lonza Looks Like Tariff Winner -- Market Talk

9 mai 2025, 14:45 UTC

Market Talk

Big Pharma's U.S. Expansion Will Take Years to Materialize, Lonza CFO Says -- Market Talk

9 mai 2025, 14:42 UTC

Market Talk

Big Pharma U.S. Investment Plans Might Not Bring Extra Spending, Lonza CFO Says -- Market Talk

8 apr. 2025, 07:34 UTC

Market Talk

Lonza Well Protected From Tariffs -- Market Talk

29 ian. 2025, 08:11 UTC

Market Talk
Câștiguri

Lonza's Outlook Looks Positive -- Market Talk

29 ian. 2025, 07:22 UTC

Market Talk
Câștiguri

Lonza Had a Mixed Year Across Divisions -- Market Talk

29 ian. 2025, 07:11 UTC

Market Talk
Câștiguri

Lonza's Results Don't Contain Any Surprises -- Market Talk

Comparație

Modificare preț

Lonza Group AG Așteptări

Obiectiv de preț

By TipRanks

20.6% sus

Prognoză pe 12 luni

Medie 668.6 CHF  20.6%

Maxim 753 CHF

Minim 603 CHF

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLonza Group AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

10 ratings

8

Cumpărare

2

Păstrare

0

Vânzare

Sentiment

By Acuity

157 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.